Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France

Table 6

Treatment sequencing: most common first- and second-line treatment regimens.

First line	N (%)	Second line	N (%)
Doxorubicin	330 (40.9)	Ifosfamide^a	63 (19.1)
		Pazopanib	24 (7.3)
		Trabectedin	19 (5.8)
		Docetaxel + gemcitabine	15 (4.5)
		Paclitaxel	5 (1.5)
		Others	16 (4.8)
		No treatment	188 (57)
Doxorubicin + ifosfamide^a	153 (19.0)	Docetaxel + gemcitabine	38 (24.8)
		Pazopanib	21 (13.7)
		Trabectedin	17 (11.1)
		Others	23 (15.0)
		No treatment	54 (35.3)
Docetaxel + gemcitabine	70 (8.7)	Doxorubicin	13 (18.6)
		Pazopanib	7 (10)
		Doxorubicin + ifosfamide^a	4 (5.7)
		Ifosfamide^a	3 (4.3)
		Others	9 (12.9)
		No treatment	34 (48.6)
Paclitaxel	34 (4.2)	Doxorubicin	3 (8.8)
		Ifosfamide^a	1 (2.9)
		No treatment	30 (88.2)
Ifosfamide-mesna	33 (4.1)	Doxorubicin	3 (9.1)
		Others	3 (9.1)
		No treatment	27 (81.8)

^aMesna was always coadministered with ifosfamide.